George Cotsarelis said in 2015 he thinks there will be multiple treatments available in a few years. The treatments are coming, he said. But he added that what may work for some may not work for everyone. All of us here are anticipating the release of one treatment or another as it stands now. It's the waiting that is the frustrating part.
Aubrey de Grey said, in 2005, “Living forever or postponing death is possible in our lifetimes.” He obviously believes the scientific theory exists or is within reach that could solve longevity. Scientists are encouraged by findings for life extension because of the work being done with mice models. Science is now able to extend the lifespans of mice by 17 to 35%. New mice models are giving hope to developing cancer immunotherapies.
Another exciting area of research is hearing loss. There are clinical trials happening now for gene therapy and stem cells. Another company has a license agreement with a university to test a cocktail of drugs to treat deafness due to age related and nerve damaged hearing loss. They hope to begin human trials in 2018.
And with Androgenetic Alopecia, there are new and existing drugs being tested in clinical trials right now. Additionally, new science is uncovering the secrets of stem cell activation in mouse HF. The cell functions of mice and human beings have many similarities and enough to be the basis of research for many existing and hopefully future drug therapies in humans. There exist now several mouse models for AA and at least one for Androgenetic Alopecia since 2009. Scientists are able to mimic DHT sensitivity in mice causing them to lose hair. What all this means is that the science likely exists to solve baldness. The scientific theory for solving baldness has made great strides. Where the science ends is in the labs of a few publicly-funded cancer researchers.
Tsuji, Follica, Replicel-Shiseido are hopefuls for the near to mid term, one to three years. But if they don't produce practical technologies, then we have to look toward publicly funded research to solve the mysteries of age related disease, that 3 to 4% of GDP plowed back into innovation and basic research by the taxpaying public. Then it's a matter of politics as to where the money goes. Scientists would love to be able to do basic research into high risk areas of disease, but the politicians and their constituents are watching. Scientists speak publicly of what their doing in areas of medical research popular with the public and voters, like cancer and AIDS. Slowly but surely the aging western world is becoming concerned with aging. But the researchers They never talk about the research they'd like to be doing.
The science behind hair loss and hair growth has come a long way, but the technology to grow hair in people lags much further behind. We have cancer researchers to thank for the recent findings for SCF and Krox20 protein discoveries which may lead to better understanding of baldness and graying hair in people. And we have publicly-funded cancer research at UCLA to thank for stumbling on stem cell activation for HF in mice. This all needs further research and testing beyond the test tubes and mice. The science is here, but the spinoff technologies lag behind.
Aubrey de Grey said, in 2005, “Living forever or postponing death is possible in our lifetimes.” He obviously believes the scientific theory exists or is within reach that could solve longevity. Scientists are encouraged by findings for life extension because of the work being done with mice models. Science is now able to extend the lifespans of mice by 17 to 35%. New mice models are giving hope to developing cancer immunotherapies.
Another exciting area of research is hearing loss. There are clinical trials happening now for gene therapy and stem cells. Another company has a license agreement with a university to test a cocktail of drugs to treat deafness due to age related and nerve damaged hearing loss. They hope to begin human trials in 2018.
And with Androgenetic Alopecia, there are new and existing drugs being tested in clinical trials right now. Additionally, new science is uncovering the secrets of stem cell activation in mouse HF. The cell functions of mice and human beings have many similarities and enough to be the basis of research for many existing and hopefully future drug therapies in humans. There exist now several mouse models for AA and at least one for Androgenetic Alopecia since 2009. Scientists are able to mimic DHT sensitivity in mice causing them to lose hair. What all this means is that the science likely exists to solve baldness. The scientific theory for solving baldness has made great strides. Where the science ends is in the labs of a few publicly-funded cancer researchers.
Tsuji, Follica, Replicel-Shiseido are hopefuls for the near to mid term, one to three years. But if they don't produce practical technologies, then we have to look toward publicly funded research to solve the mysteries of age related disease, that 3 to 4% of GDP plowed back into innovation and basic research by the taxpaying public. Then it's a matter of politics as to where the money goes. Scientists would love to be able to do basic research into high risk areas of disease, but the politicians and their constituents are watching. Scientists speak publicly of what their doing in areas of medical research popular with the public and voters, like cancer and AIDS. Slowly but surely the aging western world is becoming concerned with aging. But the researchers They never talk about the research they'd like to be doing.
The science behind hair loss and hair growth has come a long way, but the technology to grow hair in people lags much further behind. We have cancer researchers to thank for the recent findings for SCF and Krox20 protein discoveries which may lead to better understanding of baldness and graying hair in people. And we have publicly-funded cancer research at UCLA to thank for stumbling on stem cell activation for HF in mice. This all needs further research and testing beyond the test tubes and mice. The science is here, but the spinoff technologies lag behind.
Last edited:
